Abstract
Background. Researchers question whether estrogen receptorα-negative (ERN) and -positive (ERP) represent different stages of one disease or different breast cancer types.
Objective. To further examine ERα phenotypes, we stratified incident tumor characteristics in the Surveillance, Epidemiology, and End Results (SEER) Database (n = 82,488) by ERN and ERP.
Methods. Study variables included black–white race, age-at-diagnosis, and standard incident tumor characteristics. These characteristics were arbitrarily dichotomized into good versus poor prognostic factor groups, for example, good (tumor size ≤ 2.0 cm, negative axillary lymph nodes, and good histologic grade) versus poor (tumor size > 2.0 cm, positive nodes, and poor grade). Age frequency density plots were generated from the corresponding age-at-diagnosis frequency histograms. Average annual age-specific incidence rates (or risks) were adjusted to the 1970 United States standard female population.
Results. Age frequency density plots demonstrated bimodal premenopausal and postmenopausal breast cancer populations. ERN was correlated with premenopausal disease, black race, and poor prognostic factor groups, whereas ERP was associated with postmenopausal disease, white race, and favorable tumor characteristics. ERN rates increased premenopausally and then flattened to a nearly constant level after 50 years of age. ERP risk rose for most of a woman's lifetime with the greatest risk occurring between 75 and 79 years.
Conclusions. ERα exhibited bimodal age frequency distribution with a dichotomous pattern for age-specific rates, racial, and prognostic factor profiles. Menopause had a greater effect on ERN than ERP. Possible implications for breast carcinogenesis and cancer prevention are discussed in the text.
Similar content being viewed by others
References
Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52: 261–288, 1998
Easton D: Breast cancer – not just whether but when? [In Process Citation]. Nat Genet 26: 390–391, 2000
Hellman S: Natural history of small breast cancers. J Clin Oncol 12: 2229–2234, 1994
Moolgavkar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst 65: 559–569, 1980
Tarone RE, Chu KC: The greater impact of menopause on El-phon Elt breast cancer incidence: a possible explanation (United States) Cancer Causes Control, 3: 7–14, 2002
Auer GU, Fallenius AG, Erhardt KY, Sundelin BS: Progression of mammary adenocarcinomas as reflected by nuclear DNA content. Cytometry 5: 420–425, 1984
Pallis L, Skoog L, Falkmer U, Wilking N, Rutquist LE, Auer G, Cedermark B: The DNA profile of breast cancer in situ. Eur J Surg Oncol 18: 108–111, 1992
Iglehart JD, Kerns BJ, Huper G, Marks JR: Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 34: 253–263, 1995
Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R: Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 69: 1174–1181, 1992
Robertson JF: Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73: 5–12, 1996
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 406: 747–752, 2000
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874, 2001
AndersonWF, Chu KC, Chatterjee N, Brawley O, Brinton LA: Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 19: 18–27, 2001
Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37–45, 2001
Simpson JF, Page DL: Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 102: S3–S8, 1994
Percy C, Holten VV, Muir C (eds): International Classifi-cation of Diseases for Oncology. World Health Organization, Geneva, 199
Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative Methods. John Wiley & Sons, New York,1982
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 135: 185–198, 1972
Cox DR: Regression models and life-tables. J R Stat Soc B 34: 187–220, 1972
Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102–1109, 1984
Clemmesen J: Carcinoma of the breast. Br J Radiol 21: 583–590, 1948
Anderson E: Possible relationship between menopause and age at onset of breast cancer. Cancer 3: 141–410, 1950
Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB: Ethnicity and variation in breast cancer incidence. Int J Cancer 73: 349–355, 1997
Velentgas P, Daling JR: Risk factors for breast cancer in younger women. J. Natl Cancer Inst Monogr 16: 15–24, 1994
Edwards MJ, Gamel JW, Vaughan WP, Wrightson WF: Infiltrating ductal carcinoma of the breast: the survival impact of race. J Clin Oncol 16: 2693–2699, 1998
Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10: 431–437, 1999
Armitage P, Doll R: A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 11: 161–169, 19
Armitage P, Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8: 1–12, 1954
Lilienfeld AM, Johnson EA: The age distribution in female breast and genital cancers. Cancer 8: 875–882, 1955
Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer [In Process Citation]. Nat Genet 26: 411–414, 2000
Bertram JS: The molecular biology of cancer. Mol Aspects Med 21: 167–223, 2000
Loeb LA: A mutator phenotype in cancer. Cancer Res 61: 3230–3239, 2001
Nandi S, Guzman RC, Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92: 3650–3657, 1995
Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, FriedrichsWE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60: 4026–4029, 2000
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, CroninWM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388, 1998
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251–2556, 2001
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876–1881, 2000
Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes [see comments]. Cancer 83: 310–319, 1998
Phillips KA: Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18: 107S–112S, 2000
Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251, 19
Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976
Early breast cancer trialist's collaborative group. Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy. 133 Randomized Trials Involving 31,000 Recurrences and 24,000 Death Among 75,000 Women, pp. 1–15, 71–85, 199
Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326–1330, 1986
Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475–1479, 19
Peto J, Houlston RS: Genetics and the common cancers. Eur J Cancer 37(Suppl 8): 88–96, 2001
Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG: Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst 84: 872–877, 1992
De Waard F: Premenopausal and postmenopausal breast cancer: one disease or two? J Natl Cancer Inst 63: 549–552, 1979
De Waard F, Baanders-van Halewijn EA, Huizinga J: The bimodal age distribution of patients with mammary carcinoma. Cancer 17: 141–151, 1963
De Waard F, De Laive JWJ, Baanders-van Halewijn EA: On bimodal age distribution of mammary carcinoma. Br J Cancer 14: 437–448, 19
von Pirquet C. Allergie des Lebensalters, die bosartigen Geschwulste (Allergy of age, the Malignant Tumors), Thieme Verlag, Leipzig, Germany, 1930
Muguti GI: Experience with breast cancer in Zimbabwe. J R Coll Surg Edinburgh 38: 75–78, 1993
Chie WC, Chen CF, Lee WC, Chen CJ, Lin RS: Age-periodcohort analysis of breast cancer mortality. Anticancer Res 15: 511–515, 1995
Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, Berrino F: Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer 27: 981–984, 1991
Clemmesen J, Busk T: Cancer mortality among men and women in Denmark, England, and Switzerland. V. Incidence of accessible and inaccessible cancers in Danish towns and rural areas. Cancer Res 9: 415–421, 1949
Moolgavkar SH, Lee JA, Hade RD: Comparison of agespecific mortality from breast cancer in males in the United States and Japan. J Natl Cancer Inst 60: 1223–1225, 1978
Thomas DB: Breast cancer in men. Epidemiol Rev 15: 220–231, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anderson, W.F., Chatterjee, N., Ershler, W.B. et al. Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database. Breast Cancer Res Treat 76, 27–36 (2002). https://doi.org/10.1023/A:1020299707510
Issue Date:
DOI: https://doi.org/10.1023/A:1020299707510